Krystal Biotech (KRYS) Current Assets (2016 - 2026)

Krystal Biotech has reported Current Assets for 11 years, with the latest figure at $1.1 billion in Q2 2026.

• Current Assets for Q2 2026 came in at $1.1 billion, up 25.95% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 25.95% YoY), and the FY2025 annual result was $1.0 billion, up 38.08% from the prior year.
• Current Assets grew to $1.1 billion in Q2 2026, from $1.0 billion in the prior quarter.
• Over five years, Current Assets peaked at $1.1 billion in Q2 2026 and troughed at $355.4 million in Q1 2023.
• A 5-year average of $668.6 million and a median of $642.5 million in 2024 frame the typical range for Current Assets.
• The widest annual swing landed in 2023, when Current Assets slipped 18.85%; it then soared 69.44% in 2024.
• A 5-year view of Current Assets shows it stood at $383.8 million in 2022, then soared by 53.19% to $587.9 million in 2023, then climbed by 26.22% to $742.0 million in 2024, then jumped by 38.08% to $1.0 billion in 2025, then climbed by 3.42% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.1 billion in Q2 2026, $1.0 billion in Q1 2026, and $1.0 billion in Q4 2025.